Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$12.50
+0.1%
$12.50
$6.85
$12.51
$799.18M1.391.44 million shs3.07 million shs
Evolus, Inc. stock logo
EOLS
Evolus
$9.27
+0.7%
$10.02
$8.67
$17.82
$593.82M0.97754,518 shs424,231 shs
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$9.25
$9.22
$3.46
$9.28
$420.52M1.3840,890 shs178,496 shs
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$0.29
+3.7%
$0.36
$0.26
$2.83
$34.86M0.792.71 million shs1.86 million shs
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$3.55
-0.3%
$3.32
$2.23
$4.13
$176.68M1.29414,099 shs127,438 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.00%0.00%0.00%0.00%+86.49%
Evolus, Inc. stock logo
EOLS
Evolus
+0.11%+1.21%-7.62%-19.14%-13.60%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.00%0.00%0.00%0.00%0.00%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
+0.25%-20.09%-25.19%-8.62%-84.96%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
-0.84%+7.55%+8.21%+21.92%+14.84%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
0.7292 of 5 stars
1.00.00.04.50.01.70.6
Evolus, Inc. stock logo
EOLS
Evolus
3.6133 of 5 stars
3.50.00.03.50.63.30.6
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
3.5235 of 5 stars
3.51.00.04.10.62.50.0
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
4.1951 of 5 stars
3.52.00.00.01.94.23.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
2.00
Hold$12.25-1.96% Downside
Evolus, Inc. stock logo
EOLS
Evolus
3.00
Buy$23.75156.20% Upside
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.00
N/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
3.00
Buy$5.201,693.10% Upside
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
3.00
Buy$7.0097.18% Upside

Current Analyst Ratings Breakdown

Latest PBYI, EOLS, KIN, MRSN, and CDMO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/16/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $10.00
5/16/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/15/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$3.00
5/8/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
5/6/2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$4.00 ➝ $3.00
4/17/2025
Evolus, Inc. stock logo
EOLS
Evolus
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
4/10/2025
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
4/9/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
$139.91M5.71$0.15 per share80.92$3.02 per share4.14
Evolus, Inc. stock logo
EOLS
Evolus
$266.27M2.24N/AN/A$0.09 per share103.00
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$42.16M9.97N/AN/A$1.75 per share5.29
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$40.50M0.89N/AN/A($0.08) per share-3.63
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$230.50M0.76$0.85 per share4.18$1.88 per share1.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%9/8/2025 (Estimated)
Evolus, Inc. stock logo
EOLS
Evolus
-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$69.19M-$0.59N/AN/AN/A-217.63%-990.16%-48.87%8/12/2025 (Estimated)
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
$30.28M$0.774.619.34N/A16.37%49.35%18.25%7/30/2025 (Estimated)

Latest PBYI, EOLS, KIN, MRSN, and CDMO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Evolus, Inc. stock logo
EOLS
Evolus
-$0.09N/AN/AN/A$82.18 millionN/A
5/15/2025Q1 2025
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$0.21-$0.19+$0.02-$0.19$6.05 million$2.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/AN/AN/AN/AN/A
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
3.58
1.30
0.92
Evolus, Inc. stock logo
EOLS
Evolus
22.00
2.34
2.16
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.19
7.02
7.02
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/A
1.83
1.83
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
0.11
1.53
1.43

Institutional Ownership

CompanyInstitutional Ownership
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
97.16%
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
66.89%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
93.92%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
61.29%

Insider Ownership

CompanyInsider Ownership
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
3.05%
Evolus, Inc. stock logo
EOLS
Evolus
5.90%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
13.69%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
13.00%
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
23.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avid Bioservices, Inc. stock logo
CDMO
Avid Bioservices
32063.96 million62.01 millionOptionable
Evolus, Inc. stock logo
EOLS
Evolus
17064.48 million60.67 millionOptionable
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
6345.46 millionN/AOptionable
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
150124.63 million108.43 millionOptionable
Puma Biotechnology, Inc. stock logo
PBYI
Puma Biotechnology
20049.63 million38.07 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Avid Bioservices stock logo

Avid Bioservices NASDAQ:CDMO

$12.50 +0.02 (+0.12%)
Closing price 02/5/2025
Extended Trading
$12.50 0.00 (0.00%)
As of 02/5/2025 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.

Evolus stock logo

Evolus NASDAQ:EOLS

$9.27 +0.06 (+0.65%)
As of 02:38 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Kindred Biosciences stock logo

Kindred Biosciences NASDAQ:KIN

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Mersana Therapeutics stock logo

Mersana Therapeutics NASDAQ:MRSN

$0.29 +0.01 (+3.68%)
Closing price 03:57 PM Eastern
Extended Trading
$0.30 +0.01 (+1.72%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Puma Biotechnology stock logo

Puma Biotechnology NASDAQ:PBYI

$3.55 -0.01 (-0.28%)
Closing price 03:21 PM Eastern
Extended Trading
$3.54 0.00 (-0.14%)
As of 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.